Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones

Journal of Bone and Mineral Research

Volumn 26, Issue 5, 2011, Pages 1012-1021

  Ominsky, Michael S ^a   Li, Chaoyang ^a   Li, Xiaodong ^a   Tan, Hong L ^a   Lee, Edward ^a   Barrero, Mauricio ^a   Asuncion, Franklin J ^a   Dwyer, Denise ^a   Han, Chun Ya ^a   Vlasseros, Fay ^b   Samadfam, Rana ^b   Jolette, Jacquelin ^b   Smith, Susan Y ^b   Stolina, Marina ^a   Lacey, David L ^a   Simonet, William S ^a   Paszty, Chris ^a   Li, Gang ^c   Ke, Hua Z ^a  

^a AMGEN INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

FRACTURE HEALING; SCLEROSTIN; SCLEROSTIN ANTIBODY; STRENGTH; WNT

Indexed keywords

MONOCLONAL ANTIBODY; SCLEROSTIN; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MASS; BONE STRENGTH; CALLUS; CONTROLLED STUDY; FEMUR FRACTURE; FRACTURE; FRACTURE HEALING; MALE; NONHUMAN; OSSIFICATION; OSTEOTOMY; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOMECHANICS; BONE DENSITY; DIAPHYSES; DISEASE MODELS, ANIMAL; FEMORAL FRACTURES; FEMUR; FIBULA; FRACTURE HEALING; GLYCOPROTEINS; MACACA FASCICULARIS; MALE; ORGAN SIZE; OSTEOGENESIS; OSTEOTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79955635177     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.307     Document Type: Article

References (39)

1. Zuscik M, O'Keefe RJ., Skeletal healing. In:, Rosen CJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: American Society for Bone and Mineral Research, 2008: 61-65.
2. Einhorn TA., Enhancement of fracture-healing. J Bone Joint Surg Am. 1995; 77: 940-956.
3. Einhorn TA., Clinical applications of recombinant human BMPs: early experience and future development. J Bone Joint Surg Am. 2003; 85: S82-88.
4. Mont MA, Ragland PS, Biggins B, et al. Use of bone morphogenetic proteins for musculoskeletal applications: an overview. J Bone Joint Surg Am. 2004; 86: S41-55.
5. Garrison KR, Donell S, Ryder J, et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess. 2007; 11: 1-150, iii-iv.
6. Poynton AR, Lane JM., Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine (Phila Pa 1976). 2002; 27: S40-48.
7. Secreto FJ, Hoeppner LH, Westendorf JJ., Wnt signaling during fracture repair. Curr Osteoporos Rep. 2009; 7: 64-69.
8. Chen Y, Whetstone HC, Lin AC, et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med. 2007; 4: e249.
9. Kim JB, Leucht P, Lam K, et al. Bone regeneration is regulated by wnt signaling. J Bone Miner Res. 2007; 22: 1913-1923. (Pubitemid 351229308)
10. Leucht P, Kim JB, Helms JA., Beta-catenin-dependent Wnt signaling in mandibular bone regeneration. J Bone Joint Surg Am. 2008; 90 (Suppl 1): 3-8. (Pubitemid 351329113)
11. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537-543. (Pubitemid 32184286)
12. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577-589. (Pubitemid 32202753)
13. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19: 1842-1844. (Pubitemid 41598769)
14. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22: 6267-6276. (Pubitemid 37522584)
15. Hamersma H, Gardner J, Beighton P., The natural history of sclerosteosis. Clin Genet. 2003; 63: 192-197. (Pubitemid 36949919)
16. Vanhoenacker FM, Balemans W, Tan GJ, et al. Van Buchem disease: lifetime evolution of radioclinical features. Skeletal Radiol. 2003; 32: 708-718. (Pubitemid 37527086)
17. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860-869. (Pubitemid 351768804)
18. Baron R, Rawadi G., Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148: 2635-2643. (Pubitemid 46984775)
19. Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem. 2009; 284: 10890-10900.
20. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24: 578-588.
21. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25: 948-959.
22. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26: 19-26.
23. Bonnarens F, Einhorn TA., Production of a standard closed fracture in laboratory animal bone. J Orthop Res. 1984; 2: 97-101. (Pubitemid 14034681)
24. Seeherman HJ, Bouxsein M, Kim H, et al. Recombinant human bone morphogenetic protein-2 delivered in an injectable calcium phosphate paste accelerates osteotomy-site healing in a nonhuman primate model. J Bone Joint Surg Am. 2004; 86-A: 1961-1972. (Pubitemid 39232119)
25. Taylor DK, Meganck JA, Terkhorn S, et al. Thrombospondin-2 influences the proportion of cartilage and bone during fracture healing. J Bone Miner Res. 2009; 24: 1043-1054.
26. Seeherman H, Li R, Bouxsein M, et al. rhBMP-2/calcium phosphate matrix accelerates osteotomy-site healing in a nonhuman primate model at multiple treatment times and concentrations. J Bone Joint Surg Am. 2006; 88: 144-160. (Pubitemid 43062783)
27. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
28. Court-Brown CM, Koval KJ., The epidemiology of fractures. In:, Bucholz RW, Heckman JD, Court-Brown CM, eds. Rockwood and Green's Fractures in Adults. Philadelphia, PA, USA: Lippincott, 2006: 96-143.
29. Court-Brown CM, Aitken S, Hamilton TW, et al. Nonoperative Fracture Treatment in the Modern Era. J Trauma. 2010; 69: 699-707.
30. Meyer RA, Tsahakis PJ, Martin DF, et al. Age and ovariectomy impair both the normalization of mechanical properties and the accretion of mineral by the fracture callus in rats. J Orthop Res. 2001; 19: 428-435. (Pubitemid 32472013)
31. Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007; 297: 387-394. (Pubitemid 46155800)
32. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009; 301: 513-521.
33. Burr DB, Hirano T, Turner CH, et al. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001; 16: 157-165. (Pubitemid 32046201)
34. Fox J, Miller MA, Newman MK, et al. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone. 2007; 41: 321-330. (Pubitemid 47199143)
35. Stoffel K, Engler H, Kuster M, et al. Changes in biochemical markers after lower limb fractures. Clin Chem. 2007; 53: 131-134. (Pubitemid 46047773)
36. Nakajima A, Shimoji N, Shiomi K, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res. 2002; 17: 2038-2047. (Pubitemid 35239205)
37. Tagil M, McDonald MM, Morse A, et al. Intermittent PTH((1-34)) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures. Bone. 2010; 46: 852-859.
38. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010; 25: 404-414.
39. Manabe T, Mori S, Mashiba T, et al. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone. 2007; 40: 1475-1482. (Pubitemid 46756411)